Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-11-05

FDA Approved: CAPLYTA — Supplemental Application (Intra-Cellular Therapies, Inc)

View source ↗

Summary

FDA approves a supplemental application for CAPLYTA (lumateperone) from Intra-Cellular Therapies, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Caplyta (lumateperone)

Snippet

SUPPL AP for CAPLYTA (LUMATEPERONE)